Cargando…

Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer

BACKGROUND: Breast cancer (BC) immune infiltrates play a critical role in tumor progression and response to treatment. Besides stromal tumor infiltrating lymphocytes (sTILs) which have recently reached level 1B evidence as a prognostic marker in triple negative BC, a plethora of methods to assess im...

Descripción completa

Detalles Bibliográficos
Autores principales: Nederlof, Iris, De Bortoli, Davide, Bareche, Yacine, Nguyen, Bastien, de Maaker, Michiel, Hooijer, Gerrit K. J., Buisseret, Laurence, Kok, Marleen, Smid, Marcel, Van den Eynden, Gert G. G. M., Brinkman, Arie B., Hudecek, Jan, Koster, Jan, Sotiriou, Christos, Larsimont, Denis, Martens, John W. M., van de Vijver, Marc J., Horlings, Hugo M., Salgado, Roberto, Biganzoli, Elia, Desmedt, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933637/
https://www.ncbi.nlm.nih.gov/pubmed/31878981
http://dx.doi.org/10.1186/s13058-019-1239-4
_version_ 1783483246854537216
author Nederlof, Iris
De Bortoli, Davide
Bareche, Yacine
Nguyen, Bastien
de Maaker, Michiel
Hooijer, Gerrit K. J.
Buisseret, Laurence
Kok, Marleen
Smid, Marcel
Van den Eynden, Gert G. G. M.
Brinkman, Arie B.
Hudecek, Jan
Koster, Jan
Sotiriou, Christos
Larsimont, Denis
Martens, John W. M.
van de Vijver, Marc J.
Horlings, Hugo M.
Salgado, Roberto
Biganzoli, Elia
Desmedt, Christine
author_facet Nederlof, Iris
De Bortoli, Davide
Bareche, Yacine
Nguyen, Bastien
de Maaker, Michiel
Hooijer, Gerrit K. J.
Buisseret, Laurence
Kok, Marleen
Smid, Marcel
Van den Eynden, Gert G. G. M.
Brinkman, Arie B.
Hudecek, Jan
Koster, Jan
Sotiriou, Christos
Larsimont, Denis
Martens, John W. M.
van de Vijver, Marc J.
Horlings, Hugo M.
Salgado, Roberto
Biganzoli, Elia
Desmedt, Christine
author_sort Nederlof, Iris
collection PubMed
description BACKGROUND: Breast cancer (BC) immune infiltrates play a critical role in tumor progression and response to treatment. Besides stromal tumor infiltrating lymphocytes (sTILs) which have recently reached level 1B evidence as a prognostic marker in triple negative BC, a plethora of methods to assess immune infiltration exists, and it is unclear how these compare to each other and if they can be used interchangeably. METHODS: Two experienced pathologists scored sTIL, intra-tumoral TIL (itTIL), and 6 immune cell types (CD3(+), CD4(+), CD8(+), CD20(+), CD68(+), FOXP3(+)) in the International Cancer Genomics Consortium breast cancer cohort using hematoxylin and eosin-stained (n = 243) and immunohistochemistry-stained tissue microarrays (n = 254) and whole slides (n = 82). The same traits were evaluated using transcriptomic- and methylomic-based deconvolution methods or signatures. RESULTS: The concordance correlation coefficient (CCC) between pathologists for sTIL was very good (0.84) and for cell-specific immune infiltrates slightly lower (0.63–0.66). Comparison between tissue microarray and whole slide pathology scores revealed systematically higher values in whole slides (ratio 2.60–5.98). The Spearman correlations between microscopic sTIL and transcriptomic- or methylomic-based assessment of immune infiltrates were highly variable (r = 0.01–0.56). Similar observations were made for cell type-specific quantifications (r = 0.001–0.54). We observed a strong inter-method variability between the omics-derived estimations, which is further cell type dependent. Finally, we demonstrated that most methods more accurately identify highly infiltrated (sTIL ≥ 60%; area under the curve, AUC, 0.64–0.99) as compared to lowly infiltrated tumors (sTIL ≤ 10%; AUC 0.52–0.82). CONCLUSIONS: There is a lower inter-pathologist concordance for cell-specific quantification as compared to overall infiltration quantification. Microscopic assessments are underestimated when considering small cores (tissue microarray) instead of whole slides. Results further highlight considerable differences between the microscopic-, transcriptomic-, and methylomic-based methods in the assessment of overall and cell-specific immune infiltration in BC. We therefore call for extreme caution when assessing immune infiltrates using current methods and emphasize the need for standardized immune characterization beyond TIL.
format Online
Article
Text
id pubmed-6933637
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69336372019-12-30 Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer Nederlof, Iris De Bortoli, Davide Bareche, Yacine Nguyen, Bastien de Maaker, Michiel Hooijer, Gerrit K. J. Buisseret, Laurence Kok, Marleen Smid, Marcel Van den Eynden, Gert G. G. M. Brinkman, Arie B. Hudecek, Jan Koster, Jan Sotiriou, Christos Larsimont, Denis Martens, John W. M. van de Vijver, Marc J. Horlings, Hugo M. Salgado, Roberto Biganzoli, Elia Desmedt, Christine Breast Cancer Res Research Article BACKGROUND: Breast cancer (BC) immune infiltrates play a critical role in tumor progression and response to treatment. Besides stromal tumor infiltrating lymphocytes (sTILs) which have recently reached level 1B evidence as a prognostic marker in triple negative BC, a plethora of methods to assess immune infiltration exists, and it is unclear how these compare to each other and if they can be used interchangeably. METHODS: Two experienced pathologists scored sTIL, intra-tumoral TIL (itTIL), and 6 immune cell types (CD3(+), CD4(+), CD8(+), CD20(+), CD68(+), FOXP3(+)) in the International Cancer Genomics Consortium breast cancer cohort using hematoxylin and eosin-stained (n = 243) and immunohistochemistry-stained tissue microarrays (n = 254) and whole slides (n = 82). The same traits were evaluated using transcriptomic- and methylomic-based deconvolution methods or signatures. RESULTS: The concordance correlation coefficient (CCC) between pathologists for sTIL was very good (0.84) and for cell-specific immune infiltrates slightly lower (0.63–0.66). Comparison between tissue microarray and whole slide pathology scores revealed systematically higher values in whole slides (ratio 2.60–5.98). The Spearman correlations between microscopic sTIL and transcriptomic- or methylomic-based assessment of immune infiltrates were highly variable (r = 0.01–0.56). Similar observations were made for cell type-specific quantifications (r = 0.001–0.54). We observed a strong inter-method variability between the omics-derived estimations, which is further cell type dependent. Finally, we demonstrated that most methods more accurately identify highly infiltrated (sTIL ≥ 60%; area under the curve, AUC, 0.64–0.99) as compared to lowly infiltrated tumors (sTIL ≤ 10%; AUC 0.52–0.82). CONCLUSIONS: There is a lower inter-pathologist concordance for cell-specific quantification as compared to overall infiltration quantification. Microscopic assessments are underestimated when considering small cores (tissue microarray) instead of whole slides. Results further highlight considerable differences between the microscopic-, transcriptomic-, and methylomic-based methods in the assessment of overall and cell-specific immune infiltration in BC. We therefore call for extreme caution when assessing immune infiltrates using current methods and emphasize the need for standardized immune characterization beyond TIL. BioMed Central 2019-12-26 2019 /pmc/articles/PMC6933637/ /pubmed/31878981 http://dx.doi.org/10.1186/s13058-019-1239-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Nederlof, Iris
De Bortoli, Davide
Bareche, Yacine
Nguyen, Bastien
de Maaker, Michiel
Hooijer, Gerrit K. J.
Buisseret, Laurence
Kok, Marleen
Smid, Marcel
Van den Eynden, Gert G. G. M.
Brinkman, Arie B.
Hudecek, Jan
Koster, Jan
Sotiriou, Christos
Larsimont, Denis
Martens, John W. M.
van de Vijver, Marc J.
Horlings, Hugo M.
Salgado, Roberto
Biganzoli, Elia
Desmedt, Christine
Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer
title Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer
title_full Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer
title_fullStr Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer
title_full_unstemmed Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer
title_short Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer
title_sort comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933637/
https://www.ncbi.nlm.nih.gov/pubmed/31878981
http://dx.doi.org/10.1186/s13058-019-1239-4
work_keys_str_mv AT nederlofiris comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer
AT debortolidavide comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer
AT barecheyacine comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer
AT nguyenbastien comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer
AT demaakermichiel comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer
AT hooijergerritkj comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer
AT buisseretlaurence comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer
AT kokmarleen comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer
AT smidmarcel comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer
AT vandeneyndengertggm comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer
AT brinkmanarieb comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer
AT hudecekjan comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer
AT kosterjan comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer
AT sotiriouchristos comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer
AT larsimontdenis comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer
AT martensjohnwm comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer
AT vandevijvermarcj comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer
AT horlingshugom comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer
AT salgadoroberto comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer
AT biganzolielia comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer
AT desmedtchristine comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer